Strides Pharma Science Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a total income of ₹12,702.97 million, with a profit before tax of ₹1,996.16 million. The results also include other comprehensive income and detailed segment performance, providing a snapshot of the company’s financial health for the period.
Strides Pharma Announces Q1 FY27 Financial Performance
Strides Pharma Science Limited has released its unaudited consolidated financial results for the first quarter of the fiscal year 2027, which concluded on June 30, 2026. The Board of Directors approved these results during a meeting held on July 31, 2026.
Key Financial Highlights
For the quarter ended June 30, 2026, the company’s total income from continuing operations stood at ₹12,654.07 million, with additional other income contributing ₹48.90 million. This brought the total income to ₹12,702.97 million. Total expenses for the period amounted to ₹11,325.93 million. Consequently, the profit before exceptional items and tax was ₹1,377.04 million. After accounting for exceptional items of ₹631.97 million, the profit before tax (including share of profit from associates and joint ventures) was ₹1,996.16 million. The total tax expense for the quarter was ₹341.23 million, resulting in a profit for the period of ₹1,654.93 million.
Other Comprehensive Income
The company also reported other comprehensive income for the period, totaling ₹289.17 million. This, combined with the profit for the period, resulted in a total comprehensive income of ₹1,944.10 million attributable to the owners of the company and non-controlling interests.
Standalone Results
In addition to the consolidated figures, Strides Pharma also provided its standalone unaudited results. For the quarter ended June 30, 2026, standalone total income from continuing operations was ₹5,826.48 million, with a profit for the period of ₹729.28 million. The standalone total comprehensive income for the period was ₹961.84 million.
Source: BSE
